Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer

Onkologie

Volumn 33, Issue 8-9, 2010, Pages 466-469

  Li, Xiao Dong ^a,b   Geng, Yi Ting ^a   Wu, Chang Ping ^b   Shen, Hua ^a   Sun, Jing ^a   Shu, Yong Qian ^a   Yin, Yong Mei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

(TKI); Chemotherapy; Gefitinib: resistance, restoration of sensitivity; Mutations; Tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETIDRONIC ACID; GEFITINIB; PEMETREXED;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASIAN; BONE MARROW DEPRESSION; BONE METASTASIS; BRAIN DAMAGE; BRAIN METASTASIS; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSURIA; FEMALE; HEMATURIA; HUMAN; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NECK PAIN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; QUINAZOLINES; TREATMENT OUTCOME;

EID: 77956644602     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319109     Document Type: Article

References (10)

1. Miller VA, Kris MG, Shah N, et al.: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced nonsmall-cell lung cancer. J Clin Oncol 2004;22:1103-1109.
2. Riely GJ, Politi KA, Miller VA, et al.: Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006;12:7232-7241.
3. Pao W, Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-2568.
4. Yano S, Nakataki E, Ohtsuka S, et al.: Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol Res 2005;15:107-111.
5. Yokouchi H, Yamazaki K, Kinoshita I, et al.: Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer 2007;7:51.
6. Yoshimoto A, Inuzuka K, Kita T, et al.: Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib. Am J Med Sci 2007;333:221-225.
7. Kurata T, Tamura K, Kaneda H, et al.: Effect of retreatment with gefitinib (Iressa, ZD1839) after acquisition of resistance. Ann Oncol 2004;15:173-174.
8. Riely GJ, Kris MG, Zhao B, et al.: Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007;13: 5150-5155.
9. Kwak EL, Sordella R, Bell DW, et al.: Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005;102:7665-7670.
10. Engelman JA, Mukohara T, Zejnullahu K, et al.: Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006;116:2695-2706.